Skip to main content
. 2019 Apr 9;8:e39380. doi: 10.7554/eLife.39380

Figure 2. Reduced lifespan and increased tumor incidence in Kdm6a F2s.

(A) Cross for Kdm6a F2s and control F2s. The Kdm6a cKO male used in this experiment was littermate to the 3 Kdm6a cKO and two control males used in the F1 experiment. Control F2s, combined progeny of Cre-only or only Kdm6a(fl)-only F1s. (B) Survival curve for Kdm6a F1s, control F1s, and Kdm6a F2s. Hazard ratio and p-value calculated by a Cox proportional hazards model. (C) Raw counts of tumors (p=3.45e-9) and non-tumor phenotypes (p=0.13) in control F1s, Kdm6a F1s, and Kdm6a F2s at necropsy (p-values, Kdm6a F2s vs. control F1s, one-sample test of proportions). (D) H&E staining of representative tumors in Kdm6a F2s. Scale bar, 100 um (large images), 10 um (insets). (E) Tumor count per individual at necropsy. *p<0.05, **p<0.01, Fisher’s exact test. (F) Fraction of mice with tumors. *p<0.05, **p<0.01, ***p<0.001, Fisher’s exact test. See Figure 2—source data 1.

Figure 2—source data 1. Survival and cancer phenotype of Kdm6a F2s.
DOI: 10.7554/eLife.39380.018
Figure 2—source data 2. All tumors identified in F1 and F2 cohorts.
Counts represent total tumors including multiple tumors per mouse. Tumor rate (tumors/mouse) in parentheses. Kdm6a F2.controlA mice generated from a Cre-only sire; Kdm6a F2.controlB mice generated from a Kdm6a(fl)-only sire.
DOI: 10.7554/eLife.39380.019

Figure 2.

Figure 2—figure supplement 1. Survival of F2s from individual sires.

Figure 2—figure supplement 1.

Each plot shows survival of F2 offspring from an individual Kdm6a F1 control or Kdm6a male (blue), as shown in Figure 3, plotted with survival data from control F1s (grey). Kdm6a F1 control male sires #1 and #2 carried the Kdm6a(fl) allele without the Ddx4-Cre transgene. Kdm6a F1 control male sires #3 and #4 carried the Ddx4-Cre transgene without the Kdm6a(fl) allele. HR, hazard ratio. p-values calculated using a Cox proportional hazards model.
Figure 2—figure supplement 2. Counts of gross and histopathological diagnoses at necropsy for Kdm6a F1s, control F1s, and Kdm6a F2s.

Figure 2—figure supplement 2.